Oncology Brothers

In this episode of the Oncology Brothers podcast, we dived deep into the evolving landscape of HER2-positive breast cancer treatment following the significant advancements made in 2025. Joined by Dr. Virginia Kaklamani from UT Health San Antonio, we discussed the latest data from SABCS 2025 and pivotal trials such as DESTINY-Breast09, which have led to new treatment approvals and strategies. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics included: • The treatment algorithm for early-stage HER2-positive breast cancer, including the APT trial and the role of trastuzumab. • Insights into neoadjuvant and adjuvant therapies, including the implications of the neoCARHP trial regimen and the potential of T-DXd. • The impact of recent studies in metastatic HER2-positive disease, including the approval of T-DXd plus pertuzumab and the promising results from the PATINA trial. • A discussion on managing side effects and the importance of patient quality of life during treatment. Join us for an informative conversation that highlights the latest advancements in HER2-positive breast cancer care and how they can be applied in clinical practice. Don't forget to like, subscribe, and leave a review to help us reach more healthcare professionals who can benefit from these discussions! #HER2Positive, #BreastCancer, #SABCS25, #TDXd, #BreastCancerTreatment, #OncologyBrothers

In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity management. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  YouTube: https://www.youtube.com/@oncologybrothers •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ The discussion covered: • The critical role of NGS testing (tissue vs. liquid biopsy) in identifying PIK3CA, ESR1, AKT1 and PTEN alterations. • Frontline management of high-risk, endocrine-resistant disease with the inavolisib triplet (INAVO120) and its overall survival benefit. • Choosing between CDK4/6 inhibitors (abemaciclib vs. ribociclib) in de novo metastatic disease. • Post-CDK4/6 inhibitors on progression we covered, the use of oral SERDs (imlunestrant) and AKT inhibitors (capivasertib). • The "ADC explosion", sequencing T-DXd (DESTINY-Breast06), sacituzumab govitecan (TROPiCS-02), and datopotamab deruxtecan (TROPION-Breast01). • Clinical pearls for managing toxicities: stomatitis, hyperglycemia, rash, neutropenia, and ILD. Join us as we break down the latest data and provide actionable insights for the practicing oncologist. Don't forget to subscribe for more episodes in our breast cancer algorithm series! #MetastaticBreastCancer, #HRPositive, #ADCsequencing, #PIK3CA-AKT, #OncologyPodcast, #OncologyBrothers

In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain dived deep into the evolving landscape of breast cancer treatment algorithms, focusing on early and locally advanced hormone receptor-positive breast cancer. Joined by Dr. Erica Mayer, a breast medical oncologist at the Dana-Farber Cancer Institute.  Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  YouTube: https://www.youtube.com/@oncologybrothers/ •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ The discussion covered: • The role of chemotherapy in early-stage hormone receptor-positive breast cancer, including the use of anthracyclines versus taxane-based approaches. • Insights from the TAILORx trial and the implications of Oncotype DX scores in treatment decisions. • The ongoing OFSET trial and its potential impact on premenopausal patients with low recurrence scores. • The use of CDK4/6 inhibitors, including ribociclib and abemaciclib, in the adjuvant setting, along with their side effect profiles and dosing considerations. • The significance of the recent lidERA trial results featuring giredestrant and its implications for future treatment strategies. Join us as we explore the latest data, treatment paradigms, and the importance of patient-shared decision-making in breast cancer care. Don't forget to subscribe for more insights and staying up to date in the field of cancer.  #EarlyBreastCancer, #OncotypeDX, #CDK46inhibitors, #OralSERD, #AdjuvantTherapy, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we engaged in a thought-provoking discussion with Dr. Patrick Soon-Shiong, a pioneer in oncology and the innovator behind the approval of nab-paclitaxel (Abraxane). We delved into the exciting potential of Anktiva (N-803), an IL-15 receptor super agonist designed to expand and activate natural killer (NK) cells and CD8 T cells, with the hope of revolutionizing cancer treatment. Dr. Soon-Shiong shared insights into the mechanism of action of Anktiva, its current approvals in non-muscle invasive bladder cancer, and extended approval in non-small cell lung cancer in Saudi Arabia, and the promising clinical trial data that suggests a significant increase in overall survival for patients. The conversation also touched on the importance of restoring lymphocyte counts and the implications for treating various tumor types. Join us as we explore the future of immunotherapy, the challenges of regulatory approval, and the potential for Anktiva to change the landscape of cancer treatment. Key Topics: • Mechanism of action of Anktiva • Current approvals and clinical trial data • The role of lymphocyte counts in cancer treatment • Future directions for immunotherapy Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more discussions on the latest in oncology! #Oncology #CancerTreatment #Immunotherapy #IL15Agonist #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56. Key topics included: • The design and findings of the DESTINY-Breast09 trial • Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane) • The implications of these findings for clinical practice • The role of maintenance therapy and the potential for personalized treatment strategies • Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease) Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/  Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option. Episode Highlights: • Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments. • In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics. • Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects. • Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations. • Practical considerations for administering these treatments in both inpatient and outpatient settings. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals! #AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the current treatment landscape for head and neck cancer. We welcomed Dr. Fangdi Sun, a head and neck medical oncologist from Stanford University, to discuss key topics including: • The importance of initial workup and the role of biomarkers, including HPV and EBV testing. • Treatment paradigm for early-stage and locally advanced head and neck cancers, focusing on the differences between HPV-positive and HPV-negative disease. • The evolving role of immunotherapy and the new perioperative approaches in treatment. • Insights into managing metastatic disease, including the use of PD-L1 scores and systemic therapy options. • The significance of multidisciplinary collaboration in optimizing patient care. Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the complexities of head and neck cancer treatment. Don't miss out on this informative discussion! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to our channel for more episodes as we continue to bridge the gap in oncology! #HeadAndNeckCancer, #HPV, #Immunotherapy, #MultidisciplinaryCare, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention. Key topics discussed included: • The definition and classification of smoldering myeloma • The design and findings of the AQUILA trial • The significance of time to progression and overall survival in treatment • The risk-benefit analysis of daratumumab therapy, including potential side effects • Future directions in myeloma treatment and ongoing research Join us for an informative discussion as we bridge the gap between academic research and community practice, helping healthcare professionals and patients navigate the evolving landscape of myeloma treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, conference highlights, and FDA approvals!

Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond. In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-head comparisons in newly diagnosed disease, and finally, to the groundbreaking bispecific antibody data that is set to revolutionize care at first relapse. Key topics covered in this episode: ● AQUILA update: Daratumumab in high-risk smoldering myeloma, and the ongoing clinical dilemma ● COBRA: Is KRD superior to VRD in newly diagnosed multiple myeloma? Unpacking the MRD and PFS data. ● TecLILLE: A first look at Teclistamab + Daratumumab in frontline, transplant-ineligible patients. ● MajesTEC-3: PFS and OS data for Teclistamab + Daratumumab in first relapse, and its impending FDA approval. Tune in for this expert breakdown to navigate the new myeloma landscape with confidence. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe for more deep dives into treatment algorithms and major conference highlights! #OncologyBrothers #ASH2025 #MultipleMyeloma #Myeloma #SmolderingMyeloma #BispecificAntibody #Teclistamab #Daratumumab #CART

We're kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026. We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease. Key topics covered in this episode: ● MATTERHORN update: Surgical outcomes & FLOT modifications with Durvalumab in resectable gastric/GEJ cancer ● HERIZON-GEA-01: Zanidatamab + chemo + Tislelizumab the new frontline standard for HER2+ gastric cancer ● BREAKWATER: Confirming Encorafenib + Cetuximab + chemo (FOLFOX or FOLFIRI) for BRAF V600E mCRC ● COMMIT: Chemo + Atezolizumab vs. Atezolizumab alone in MSI-H/dMMR metastatic colorectal cancer Tune in for this dense, insightful recap and stay ahead of the curve. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more expert analysis on treatment algorithms and major conference highlights! #OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL). Episode Highlights: ● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma ● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab ● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments ● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerability Join us as we unpack these practice-changing studies and discuss their implications for community oncologists. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights and highlights from oncology conferences! #ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch

In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings, the potential for hypomethylating agents in treatment regimens, and the evolving landscape of CML therapies, including the promising results from the ASK4FIRST/ASK2ESCALATE featuring Asciminib. Key topics covered in this episode: ● The PARADIGM trial and its impact on AML treatment strategies ● Real-world evidence on shortened venetoclax dosing ● The role of menin inhibitors in combination therapies ● Patient-reported outcomes and quality of life with asciminib in CML Tune in for an insightful discussion on the future of leukemia treatment and the importance of patient-centered care.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on treatment algorithms, recent approvals, and conference highlights! #OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology

Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease. Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD). Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer. Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights! Topics Covered: • DESTINY Breast-11 and its impact on neoadjuvant therapy • Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease • HER2CLIMB-05 trial findings and implications for metastatic disease • The role of T-DXd with pertuzumab in frontline settings • The PATINA trial and its significance for triple-positive metastatic breast cancer Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer

In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC). Join us as we discussed: * The RJBC 1501 study, which explored the role of carboplatin in high-risk early-stage TNBC and its impact on disease-free survival. * Insights from the CITRIN study, which questions the carboplatin paradigm and highlights modern treatment approaches. * The TBCRC-056 and OlympiaN trials, investigating the combination of PARP inhibitors and immunotherapy in patients with germline BRCA and PALB2 mutations. We unpacked the implications of these studies for clinical practice, including the potential benefits and challenges of incorporating carboplatin and novel therapies into treatment regimens. Tune in for an informative discussion that aims to keep you updated on the evolving landscape of breast cancer treatment! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights from the world of oncology! #SABCS2025 #TNBC #PARPinhibitors #BRCAmutation #ChemoFree #OncologyBrothers #BreastCancer #SABCS25

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study. We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients. Key topics covered in this episode included: • Overview of the Keynote-905/EV-303 study and its significance • Comparison with previous studies like the NIAGARA trial • Discussion on the side effects of EV Pembro and management strategies • The role of ctDNA in guiding post-operative therapy • Future directions in bladder cancer research and upcoming trials Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology! #BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer. Join us as we discussed: • The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies • Insights into second-line treatment options, including the VIKTORIA-1, evERA, EMBER-3, SERENA-6 trials • A critical look at the ASCENT-07 study, exploring the role of antibody-drug conjugates (ADCs) in endocrine-resistant disease We were thrilled to have Dr. Hope Rugo, a world-renowned breast medical oncologist from City of Hope, share her expertise and insights on these pivotal studies. Tune in for an informative discussion that unpacks the latest advancements in treatment options for metastatic hormone receptor-positive breast cancer, and learn how these findings may impact clinical practice. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #MBC #HRpositive #CDK46 #ADCs #OncologyBrothers

In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer. Join us as we dive into three key abstracts: 1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies. 2. lidERA Study: Learn about the promising data on the oral selective estrogen receptor degrader (SERD) giredestrant, which shows significant improvement in invasive disease-free survival compared to standard endocrine therapy. 3. NATALEE Trial: Get insights into the five-year update on ribociclib in combination with aromatase inhibitors, highlighting its benefits across different patient subgroups (stages, nodal status). We explored the evolving landscape of endocrine therapy, the importance of side effect profiles, and how these findings may influence clinical practice moving forward. Don't miss this informative discussion that could reshape your approach to treating early-stage hormone receptor-positive breast cancer! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to our channel for more updates on treatment algorithms, recent approvals, and conference highlights. #SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC

In this episode of the Oncology Brothers podcast, we dived into the latest discussions surrounding metastatic colorectal cancer, focusing on treatment strategies for refractory cases. We recapped our recent discussions with GI experts, including Dr. John Strickler, Dr. Chiara Cremolini, Dr. Namrata Vijayvergia, and Dr. Tiago Biachi. Key topics included: * The importance of next-generation sequencing (NGS) and biomarker testing in treatment planning. * An overview of second-line treatment options such as Tas-102 with Bevacizumab, Regorafenib, and Fruquintinib, along with their respective clinical trial data. * Insights into side effect management and quality of life considerations for patients undergoing palliative treatment. * A discussion on the recent STELLAR-303 study and its implications for immunotherapy in colorectal cancer. Join us as we bridge the gap between academia and community practice, emphasizing the need for improved treatment options and patient care in the realm of refractory colorectal cancer. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more practice-changing updates! #ColorectalCancer #mCRC #TAS102 #Regorafenib #PalliativeCare #OncologyBrothers #GIOcology

In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression. Key topics include: • The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options. • The definition and implications of low and ultra-low HER2 expression in clinical practice. • The importance of HER2 testing and the dynamic nature of HER2 expression in tumors. • Treatment sequencing strategies, including the use of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (TDXd) and sasituzumab govitecan. • Management of treatment-related toxicities, including ILD, nausea, and alopecia. Join us for an insightful discussion that aims to keep healthcare professionals updated on the latest advancements in cancer care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes and insights!

Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University. Building on their previous discussion of upper GI treatment algorithm with Dr. Rutika Mehta, this episode delves into the practical realities of managing patients on complex regimens. Drs. Ku & Patel break down the side effect profiles across the treatment continuum—from frontline trastuzumab-based combinations to emerging therapies like zanidatamab—and provide actionable strategies for community oncologists. Episode Highlights: • Practical management of frontline side effects with FOLFOX/XELOX chemotherapy plus trastuzumab and pembrolizumab • Reality check on trastuzumab cardiotoxicity: incidence rates and monitoring protocols in gastric vs. breast cancer • Immune-related adverse events with checkpoint inhibitors: what's common vs. rare in GI cancers • Critical insights on zanidatamab's synergistic diarrhea toxicity and mandatory prophylaxis strategies • TDXd (Enhertu) in second-line: moving beyond ILD fears to address frequent cytopenias and marrow management • Expert consensus on infusion reaction management for novel biologics • The importance of managing baseline symptoms in patients with dysphagia and nausea This episode bridges the gap between trial data and clinical practice, offering real-world wisdom on keeping patients on effective therapies through proactive toxicity management. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for our complete CME series covering treatment algorithms, FDA approvals, and practical management strategies! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/navigating-the-adverse-event-landscape-in-her2-gea-therapy

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease. Episode Highlights: • Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings. • Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options. • Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status. • The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions. • Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape. • Considerations for managing side effects and the importance of treatment sequencing in palliative care. Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications    #HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V). We explored the side effect profiles of these therapies, focusing on critical toxicities such as interstitial lung disease (ILD), mucositis, and peripheral neuropathy. Dr. Sands shared valuable clinical pearls on managing these adverse events, emphasized the importance of proactive monitoring and patient education. Key topics covered in this episode: • Overview of ADCs and their role in NSCLC treatment • TDXd: alopecia, ILD, fatigue, nausea/vomiting • Dato-DXd:  cytopenias, mucositis, dry eyes • Teliso-V: peripheral neuropathy, fatigue, peripheral edema • The evolving landscape of ADCs and future directions in lung cancer treatment Whether you're a healthcare professional or someone interested in oncology, this episode provides essential insights into the management of side effects associated with these innovative therapies. Tune in for practical advice and expert opinions that can enhance patient care in the community setting. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on practice-changing discussions in oncology! #ADC #NSCLC #TDXd #DatoDXD #TelisoV #ToxicityManagement #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we welcomed Dr. Neil Iyengar and Dr. Emily Gallagher, to dive deep into the world of PIK3CA and AKT pathway inhibitors for hormone receptor-positive (HR+) metastatic breast cancer. We discussed the latest approvals, including Inavolisib, Alpelisib, and Capivasertib, and explored their common side effects such as hyperglycemia, rash, and gastrointestinal issues. Our experts shared practical management strategies, dosing considerations, and the importance of patient education to ensure safe and effective treatment. Key topics covered in this episode: • Overview of PIK3CA and AKT inhibitors • Common side effects and their management • The significance of proactive patient education • Dosing strategies and when to consider dose modifications • Insights on managing hyperglycemia and gastrointestinal symptoms This episode is packed with valuable information to enhance your understanding of these important therapies in the breast cancer world. Don't forget to subscribe for more episodes on treatment algorithms, toxicities, and the latest in oncology! #PI3Kinhibitors #BreastCancer #Hyperglycemia #ToxCheck #MetastaticBC #OncologyBrothers #TargetedTherapy

Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios: 1. Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and ferritin levels, exploring treatment options including the safety and efficacy of IV iron versus oral iron. 2. Anemia with Mixed Etiologies: We analyzed a case involving a 78-year-old man with a history of prostate cancer, diabetes, and chronic kidney disease, discussing the broad differential diagnosis and the role of bone marrow biopsy and molecular studies. 3. Iron Overload: We examined a 47-year-old woman with elevated ferritin levels and a heterozygous hemochromatosis mutation, debating the necessity of phlebotomy and the importance of liver imaging. Throughout the episode, we emphasized the significance of a comprehensive iron panel and the clinical context in diagnosing and managing these conditions. Dr. Beltrami shared valuable insights on the use of erythropoietin-stimulating agents in chronic kidney disease and the potential risks associated with their use. Tune in for an informative discussion packed with practical insights for healthcare professionals dealing with iron-related disorders! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. We are the Oncology Brothers! #Anemia #IronDeficiency #Hemochromatosis #IronOverload #Hematology #Ferritin #OncologyBrothers 

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates. Key topics included: • The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3. • Study design and findings from the EPCOR FL1 trial. • Step-up dosing schedule and its implications for patient management. • Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). • The role of minimal residual disease (MRD) and ctDNA in treatment decisions. Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates. Key topics included: • The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3. • Study design and findings from the EPCOR FL1 trial. • Step-up dosing schedule and its implications for patient management. • Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). • The role of minimal residual disease (MRD) and ctDNA in treatment decisions. Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases. We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines. Key topics included: • The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment • The impact of disease progression on treatment decisions • Side effect management and the importance of palliative care • The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers! #RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma. Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including: • The significance of the study in the context of recent FDA approvals and treatment advancements. • Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab. • The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes. • Management of side effects and clinical pearls for practitioners. We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions. Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, share, and subscribe for more practice-changing updates in oncology! #MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology

In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings. Key topics included: • The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib. • Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management. • Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation. • The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting. Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes and send us your challenging cases for future discussions! #CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer. Key topics included: The definition and characteristics of high-risk non-muscle invasive bladder cancer. Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment. The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach. Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy. Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes. Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology! #NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML).  We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML. Key topics covered in this episode included: The mechanism of action of Ziftomenib as a menin inhibitor Study findings from KOMET-001 and patient response rates Management of side effects, including differentiation syndrome and QTc prolongation Comparison with other menin inhibitors like Revumenib Future directions for combination therapies and sequencing of treatments Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information.  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights. #Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients. Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed: • The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC. • A detailed overview of ROS1 TKIs, including crizotinib, repotrectinib, entrectinib, taletrectinib. • Common side effects associated with these agents, such as fatigue, dizziness, edema, and liver toxicity. • Clinical pearls for managing adverse events and optimizing patient care. • The significance of patient education and regular follow-ups in ensuring treatment adherence and safety. Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into the practical aspects of treating ROS1 fusion positive NSCLC. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice! #ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer. Episode Highlights: MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach. FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with chemotherapy for EGFR-positive NSCLC. SOHO-01 & Beamion LUNG-1: emerging HER2-positive NSCLC treatments, Zongertinib and Sevabertinib. Discussion on the significance of NGS testing in identifying mutations and tailoring treatment options for patients. Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care.  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on practice-changing research and major conference highlights! #ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice. Episode Highlighted: •⁠  ⁠ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage colon cancer. •⁠  ⁠STELLAR-303: Learn about the promising results of immunotherapy in refractory MSI-stable colorectal cancer and the associated toxicities. •⁠  ⁠MATTERHORN: Updated data on durvalumab with FLOT in the perioperative setting is changing the standard of care for upper GI malignancies. •⁠  ⁠FORTITUDE-101 Study: FGFR2b target in metastatic gastric and GE junction adenocarcinoma. Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms. #ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine

In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer. We dived deep into the most impactful studies, including: • MonarchE/NATALEE: Discover additional follow-up results from abemaciclib and ribociclib, where abemaciclib now has overall survival benefit in adjuvant HR+ settings. • Metastatic HR+ Disease: Insights on the latest data surrounding PIK3CA mutations, with results from the VIKTORIA1 trial with Gedatolisib, and evERA study with Giredestrant.  • HER2+ Breast Cancer: A comprehensive look at the DESTINY trials, highlighting the efficacy of Trastuzumab Deruxtecan (TDXd) in both neoadjuvant, adjuvant and palliative settings. • Triple Negative Breast Cancer: The role of sacituzumab and Dato-DXd in the first-line treatment landscape. Join us as we unpack these complex studies, discuss clinical implications, and share practical insights for community oncologists. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #ESMO2025 #BreastCancer #MonarchE #NATALEE #DESTINYtrials #CDK4/6 #ADCs #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Sharyn Lewin, the Director of Gynecology Oncology at Holy Name Medical Center, to explore the evolving treatment landscape of ovarian cancer. Join us as we discuss: • The importance of surgical staging and debulking surgery in ovarian cancer treatment. • The role of neoadjuvant chemotherapy and the significance of germline testing. • Current systemic treatment paradigms, including the use of PARP inhibitors and Bevacizumab. • Insights into the management of refractory disease and the latest options available for patients. • The impact of biomarker testing and the importance of understanding HRD status. Dr. Lewin shared her expertise on the latest clinical data, treatment strategies, and the implications of testing for patients and their families. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell to stay updated on our upcoming episodes, including our next discussion on endometrial cancer! #OvarianCancer #PARPinhibitors #GermlineTesting #GynOnc #OncologyBrothers #MaintenanceTherapy #PersonalizedMedicine

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care. Episode Highlights: ⁠PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved radiographic progression-free survival when combined with ADT and ARPIs. Capitello-281: Highlights the use of Capivasertib in patients with PTEN loss, showing significant improvements in radiographic PFS. Potomac: Examining the role of durvalumab + BCG in high-risk non-muscle invasive bladder cancer, and the promising results from the Keynote 905 study involving enfortumab and pembrolizumab. IMVigor011: Delved into showcasing how ctDNA-guided therapy with atezolizumab can improve survival outcomes. Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers

Join us for another insightful episode of The Oncology Brothers as we dive into the Challenging Case Series! In this episode, we were joined by Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, to discuss the complexities of treating EGFR-positive non-small cell lung cancer (NSCLC). We explored the latest treatment options, including: •⁠  ⁠Osimertinib •⁠  ⁠Amivantamab plus Lazertinib (based on the MARIPOSA trial) •⁠  ⁠Osimertinib plus chemotherapy (from the FLAURA2 trial) Listen in as we analyze real-life patient cases, focusing on a 58-year-old gentleman with CNS involvement and a 66-year-old woman experiencing disease progression after initial treatment. Dr. Singhi shared valuable insights on the importance of supportive care, the impact of treatment combinations, and the significance of repeat tissue profiling. Key topics covered: •⁠  ⁠The latest data from the MARIPOSA and FLAURA2 trials •⁠  ⁠Strategies for managing side effects and improving patient quality of life •⁠  ⁠The role of multidisciplinary teams in treatment planning •⁠  ⁠The importance of understanding resistance patterns in treatment decisions Whether you're a healthcare professional or simply interested in oncology, this episode is packed with essential information and expert perspectives.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from The Oncology Brothers! #EGFRNSCLC #Mariposa #Amivantamab #Osimertinib #FLAURA2 #OncologyBrothers #LungCancer

In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib. Key topics discussed include: •⁠  ⁠The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings. •⁠  ⁠Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea. •⁠  ⁠The importance of shared decision-making with patients regarding treatment options. •⁠  ⁠Insights into the latest clinical trial data and its implications for practice. Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies! #CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC

In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML). Join us as we dive into the essential aspects of CML treatment, including: •⁠  ⁠The importance of initial workup and bone marrow biopsy in diagnosing CML. •⁠  ⁠Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib. •⁠  ⁠Patient-centered decision-making and how to align treatment options with individual patient goals. •⁠  ⁠Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD). •⁠  ⁠The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities. •⁠  ⁠Insights into the role of transplant in accelerated and blast phases of CML. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights. #CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes

Welcome to the Oncology Brothers podcast! In this Challenging Cases episode, we take a deep dive into thrombocytopenia management—a common yet often perplexing topic in everyday hematology and oncology practice. We are joined by Dr. Ronak Mistry, hematologist at the University of Pennsylvania and co‑host of Fellows on Call, to walk through real‑world cases spanning ITP, anticoagulation with low platelets, and HIT. We covered essential topics such as: • Workup of thrombocytopenia and confirming the diagnosis of ITP • First‑ and second‑line ITP therapy—steroids, IVIG, TPO receptor agonists, and splenectomy • ⁠Managing anticoagulation in thrombocytopenic patients with cirrhosis and DVT • ⁠Step‑by‑step approach to suspected HIT in the inpatient setting • Rapid‑fire tips—transfusion thresholds, chemo‑related thrombocytopenia, and medication culprits Whether you're a hematologist, oncologist, or internal medicine resident, this episode is packed with case‑based teaching points, practical pearls, and the latest guidance from ASH and NCCN for non‑malignant hematology. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more challenging case discussions, treatment strategies, and expert insights from the world of hematology and oncology! #Thrombocytopenia #HematologyPodcast #ITP #HIT #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dive deep into the latest advancements in treating extensive stage small cell lung cancer (SCLC), focusing on the IMforte data and its clinical implications. We welcomed esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Dr. Stephen Liu to discuss the findings presented at ASCO 2025 and World Lung 2025. Key topics included: • Overview of the IMforte study design and patient population • The role of lurbinectedin and atezolizumab as maintenance therapy • Significant improvements in progression-free survival (PFS) and overall survival (OS) • Management of side effects and the importance of prophylactic growth factors • Patient selection criteria for this new standard of care With a focus on bridging the gap between community and academia, this episode provides valuable insights for medical oncologists and patients alike. Tune in to learn how these advancements are changing the landscape of SCLC treatment and improving patient outcomes.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other discussions on recent approvals, treatment algorithms, and challenging cases. We are the Oncology Brothers! #IMforte #SCLC #Lurbinectedin #MaintenanceTherapy #ASCO2025 #OncologyBrothers #ES-SCLC

Welcome to the Oncology Brothers podcast! In this episode, we dive into the evolving landscape of neuroendocrine tumors (NETs) with guests Dr. Heloisa Soares, a medical oncologist, and Prof. Ken Herrmann, a nuclear medicine specialist. Together, we explored the role of Peptide Receptor Radionuclide Therapy (PRRT), imaging breakthroughs, and treatment sequencing to optimize outcomes for NET patients. We cover essential topics such as: •⁠ ⁠The role of Gallium-68 and Copper-64 DOTATATE PET imaging in diagnosis and planning •⁠ ⁠Second-line standard use of PRRT and emerging data for first-line therapy •⁠ ⁠Toxicities of PRRT—nausea, kidney toxicity, and bone marrow suppression •⁠ ⁠Balancing sequencing strategies in well-differentiated and higher-grade tumors •⁠ ⁠The critical role of multidisciplinary tumor boards in NET management •⁠ ⁠Future directions including PRRT retreatment and ongoing clinical trials Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology! #NeuroendocrineTumors #NETs #PRRT #OncologyBrothers #CancerTreatment #NuclearMedicine

Welcome to the Oncology Brothers podcast! In this episode we we deep into the complexities of venous thromboembolism (VTE) with Drs. Jennifer Vaughn and Nicolas Gallastegui Crestani from The Ohio State University. Join us as we explore real-life VTE scenarios, discussing both provoked and unprovoked events, treatment durations, and cancer-associated cases. We cover essential topics such as: •⁠  ⁠The workup for hypercoagulable states in young patients •⁠  ⁠Long-term anticoagulation strategies for high-risk individuals •⁠  ⁠The role of D-dimer and risk scores in decision-making •⁠  ⁠Management of anticoagulation in patients with cancer undergoing treatment •⁠  ⁠Rapid-fire scenarios including superficial vein thrombosis and portal vein thrombosis Whether you're a healthcare professional or simply interested in the latest in oncology and hematology, this episode is packed with valuable insights and practical guidance. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology! #VTE #Anticoagulation #DOACs #Hematology #MedEd #OncologyBrothers #Thrombosis #Clots #DVT #PE

In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma. We covered a wide range of topics, including: •⁠  ⁠The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation. •⁠  ⁠The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients. •⁠  ⁠Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808. •⁠  ⁠The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring. •⁠  ⁠The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors. Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights! #Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dive deep into the world of neuroendocrine tumors (NETs) with renowned expert Dr. Thor Halfdanarson from the Mayo Clinic. Join us as we explore: •⁠  ⁠The critical factors in diagnosing NETs, including origin, grade, histological features, and Ki-67. •⁠  ⁠The importance of differentiating between functional and non-functional tumors and how this impacts treatment decisions. •⁠  ⁠Dr. Halfdanarson's treatment paradigm, including the use of somatostatin analogs, radioligand therapy, and other targeted treatments. •⁠  ⁠Monitoring strategies for patients, including the role of imaging and tumor markers like 5-HIAA and chromogranin. •⁠  ⁠Insights into the evolving role of immunotherapy and next-generation sequencing in managing high-grade neuroendocrine carcinomas. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information and practical insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on cutting-edge cancer treatments and expert opinions in the field of oncology!

Join us in this episode of the Oncology Brothers podcast as we dive into the highlights from the World Conference on Lung Cancer 2025! We are joined by Dr. Balazs Halmos, a thoracic medical oncologist at the Montefiore Einstein Cancer Center, to discuss three pivotal studies that are shaping the future of lung cancer treatment. In this episode, we covered: •⁠  ⁠FLAURA2 Trial: Discover the significant overall survival benefits of combining osimertinib with chemotherapy for patients with EGFR-positive non-small cell lung cancer, and how it compares to single-agent osimertinib. •⁠  ⁠HARMONi Trial: Explore the intriguing yet complex findings of a new bi-specific antibody targeting PD-1 and VEGF in patients with progressive EGFR-mutated disease, and the implications of its current negative results. •⁠  ⁠ALCHEMIST Trial: Learn about the role of crizotinib in the adjuvant setting for ALK-positive lung cancer and why it reinforces alectinib as the standard of care. Tune in for an insightful discussion on the latest advancements in precision medicine, the importance of ctDNA, and the evolving landscape of lung cancer treatment.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Join us for an insightful episode as we dive deep into the evolving landscape of Chronic Lymphocytic Leukemia (CLL) treatment. This episode features Dr. Mazyar Shadman, an expert in lymphoid malignancies from the Fred Hutch Cancer Center. In this episode, we covered: • The importance of shared decision-making in CLL treatment. • When to initiate treatment for newly diagnosed CLL patients. • The role of time-limited venetoclax-based regimens versus continuous BTK inhibitors. • Key considerations in choosing the right BTK inhibitor and managing side effects. • The relevance of minimal residual disease (MRD) in treatment duration. • Sequencing strategies for relapsed and refractory CLL, including the use of Pirtobrutinib and CAR-T therapy. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and practical advice. Don't forget to like, subscribe, and leave us your feedback! Your support helps us bring these important discussions to a wider audience. Tune in now and stay informed about the latest in CLL treatment! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ #Ibrutinib #acalabrutinib #zanubrutinib #Pirtobrutinib #CLL2025 #BTKinhibitors #Venetoclax #MRDnegative #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments. We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab. Key topics covered in this episode: •⁠  ⁠Overview of the current treatment landscape and new data from ASCO 2025 •⁠  ⁠Common side effects associated with lurbinectedin and immunotherapy •⁠  ⁠Strategies for managing adverse events, including hematologic toxicities and liver function monitoring •⁠  ⁠The role of supportive care and palliative care in enhancing patient quality of life •⁠  ⁠Collaboration between community oncologists and academic centers for optimal patient care Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease. Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ #SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rohit & Rahul Gosain are joined by Dr. Joshua Sabari from the NYU Langone Cancer Center to discuss the exciting recent approval of Zongertinib, the first oral TKI for HER2-positive lung cancer. We dived deep into the prevalence of HER2 mutations in non-small cell lung cancer, the study design and findings from the Beamion LUNG-1 trial, and the implications of this new therapy in clinical practice. Dr. Sabari shared insights on the efficacy of Zongertinib, including impressive response rates and progression-free survival data, as well as its side effect profile compared to other treatments like trastuzumab deruxtecan (T-DXd). Key topics covered in this episode: •⁠  ⁠Overview of HER2 mutations in lung cancer •⁠  ⁠Study design and results of the Beamion LUNG-1 •⁠  ⁠Comparison of Zongertinib and T-DXd in treatment settings •⁠  ⁠Management of common side effects associated with Zongertinib •⁠  ⁠Future directions for HER2-targeted therapies Join us for this informative discussion as we explore the latest advancements in lung cancer treatment and what they mean for patients and clinicians alike. Don't forget to subscribe for more episodes on new approvals, side effect management, and practice-changing data in oncology! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/